© 2020 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Prostate Cancer
Making Treatment and Screening Decisions for Patients With Prostate Cancer
July 08, 2020
Hagen F. Kennecke, MD, MHA, FRCP, medical oncologist, medical director of the Virginia Mason Cancer Institute and current chair of the NCI Rectal-Anal Cancer Task Force, discusses the treatment and screening decision making process for patients with prostate cancer.
Updated Guidelines Focus on Advanced Prostate Cancer
June 29, 2020
"Men with advanced prostate cancer have exhausted local therapies and are now moving on to systemic options."
Darolutamide OS Stands Up to Other Approved Drugs for the nmCRPC
June 28, 2020
In an interview with Targeted Oncology, Neal Shore, MD, director, Carolina Urologic Research Center, discussed the OS analysis for the phase 3 ARAMIS study and explained a match-adjusted indirect comparison. He also discussed how these data connect with presentations around the 3 approved agents for nmCRPC being presented at AUA 2020.
FDA Grants Priority Review to Relugolix for Men With Advanced Prostate Cancer
June 22, 2020
Oral relugolix received a priority review designation from the FDA for the treatment of patients with advanced prostate cancer.
Ipatasertib/Abiraterone Triplet Improves Radiographic PFS in mCRPC With PTEN Loss
June 19, 2020
“The early results of the IPATential150 study are encouraging in our ongoing mission to develop new treatment options for people with advanced prostate cancer.”
Preventative Measures and Cancer Screening Recommendations Aid Male Population
June 17, 2020
"Cancer is now the number 1 cause of death in many parts of the United States and overall, men are at a 50% likelihood of having some sort of cancer diagnosed in their lifetime, where it is slightly lower in women at about a third."
Results Demonstrate Accuracy of the 68Ga-PSMA-11 PET for Prostate Cancer
June 16, 2020
Thomas Hope, MD, discusses the efficacy of the 68Ga-PSMA-11 PET for the detection of pelvic nodal metastases in patients intermediate- to high-risk prostate cancer considered for radical prostatectomy with lymph node dissection.
Tissue-Based Assay Tests Similarly Across Racial Lines in Newly Diagnosed Prostate Cancer
June 13, 2020
In an interview with Targeted Oncology following the American Urological Association Virtual Annual Meeting, Eric A. Klein, MD, discussed the importance of molecular testing in Caucasian and African American patients with newly diagnosed prostate cancer. He also discussed the pros and cons of active surveillance.
Katz Explains the Role of Different Stratification Strategies in Prostate Cancer
June 09, 2020
In an interview with Targeted Oncology, Aaron E. Katz, MD, FACS, discussed the findings from a study of the 17-gene Oncotype DX Genomic Prostate Score.
Morgans Discusses How to Sequence Therapies in Metastatic CRPC
June 08, 2020
Alicia K. Morgans, MD, MPH, discussed treatment and testing strategies for metastatic castration-resistant prostate cancer.